SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-13-387156
Filing Date
2013-10-01
Accepted
2013-10-01 16:05:00
Documents
4
Period of Report
2013-10-01
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.04: Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.01: Changes in Control of Registrant
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K d604099d8k.htm 8-K 35110
2 EX-3.1 d604099dex31.htm EX-3.1 5139
3 EX-3.2 d604099dex32.htm EX-3.2 112571
4 EX-4.1 d604099dex41.htm EX-4.1 25247
  Complete submission text file 0001193125-13-387156.txt   179842
Mailing Address 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080
Business Address 249 E. GRAND AVE. SOUTH SAN FRANCISCO CA 94080 650-266-0000
ONYX PHARMACEUTICALS INC (Filer) CIK: 0001012140 (see all company filings)

IRS No.: 943154463 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-28298 | Film No.: 131126979
SIC: 2836 Biological Products, (No Diagnostic Substances)